Kyinno Biotechnology, Inc. provides antibody humanization services through homology modeling, framework selection, and structure-guided sequence optimization.

Kyinno Biotechnology: Pioneering Oncology Research as a Premier CRO Global Presence: Strategically positioned in Beijing and Boston, Kyinno Biotechnology leads in global oncology research and development. Advanced Resources: With over 8,000 engineered cell lines, we specialize in customized research services for drug R&D, both in vitro and in vivo. Innovative Platforms: Our MPSA-AB5000 platform exemplifies our prowess in high-throughput CART and antibody drug off-target screening, showcasing our technological capabilities. Extensive Facilities: Our state-of-the-art laboratories span over 6,000 square meters, equipped to drive forward pioneering research in oncology. Global Collaboration: Partnering with over 700 entities worldwide, we excel in building enduring relationships in the scientific community. Our Ethos: Service, Focus, Quality, and Efficiency define our approach, positioning us as a reliable partner in the quest to conquer cancer. Connect with Us: Stay informed on the latest developments at Kyinno Biotechnology by following us. We are actively interested in establishing long-term partnerships to explore new frontiers in our field.